Karyopharm and Menarini Receive MHRA’s Marketing Authorization of Nexpovio (selinexor) for the Treatment of Multiple Myeloma
Shots:
- The MHRA has granted full marketing authorization of Nexpovio (exportin 1 inhibitor) for adult patients with MM in combination with bortezomib (qw) & low-dose dexamethasone (SVd) who have received 1 prior therapy
- The approval was based on the P-III study (BOSTON) evaluating the efficacy, safety & health-related QoL of selinexor + bortezomib & low-dose dexamethasone (SVd) vs bortezomib + low-dose dexamethasone (Vd) in 402 adult patients
- The results showed a significant reduction in the risk of disease progression or death. The results were published in The Lancet. Nexpovio is marketed as Xpovio in the US & Nexpovio's marketing authorization is valid in the EU Member States, Iceland, Liechtenstein, Norway & Northern Ireland
Ref: PR Newswire | Image: Karyoharm
Related Post:- Karyopharm and Menarini's Nexpovio (selinexor) Receive EC's Marketing Authorisation for the Treatment of Multiple Myeloma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
